---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-011104"
form_type: "8-K"
ticker: "KYMR"
cik: "0001815442"
company_name: "Kymera Therapeutics, Inc."
filed_at: "2026-01-13T23:59:59+00:00"
generated_at: "2026-05-16T10:41:51.694637+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Kymera reports $1.6B cash; KT-621 Phase 2b AD data by mid-2027, asthma data late-2027

## Summary
- Preliminary cash, cash equivalents and marketable securities of $1.6B as of Dec 31, 2025; runway into 2029.
- KT-621 Phase 2b BROADEN2 trial in AD enrolling, data expected by mid-2027; BREADTH Phase 2b asthma trial initiated, data late-2027.
- KT-579 Phase 1 healthy volunteer trial expected to start 1Q26 with data in 2H26; IRF5 degrader for lupus, RA.
- At least one new first-in-class oral immunology development candidate to advance towards IND in 2026.
- Partnered programs: KT-485/SAR447971 (IRAK4) with Sanofi Phase 1 expected in 2026; CDK2 program with Gilead ongoing.

## SEC filing metadata
- accession: 0001193125-26-011104
- form_type: 8-K
- ticker: KYMR
- cik: 0001815442
- company_name: Kymera Therapeutics, Inc.
- filed_at: 2026-01-13T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1815442/000119312526011104/0001193125-26-011104-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1815442/000119312526011104/d78447d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-011104
- JSON: https://secwatch.observer/filing/0001193125-26-011104.json
- Plain text: https://secwatch.observer/filing/0001193125-26-011104.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.